Chris Blackwell
Dr Blackwell joined the Board of AGI Therapeutics plc in July 2006. He is chief executive officer of Vectura plc. Vectura is a UK-based pulmonary product development company listed on London’s Alternative Investment Market. Dr Blackwell joined Vectura in October 2002 and was appointed CEO in February 2004. He led the company’s flotation in July 2004, raising £20m, and more recently, in June 2006, raised £45m in a secondary placing.
Dr Blackwell trained as a research scientist at the University of Bath, where he completed his doctorate in 1988. He joined Glaxo Research and Development in 1988 as a Clinical Pharm-acologist and progressed to a management role before moving to Hoffman La-Roche, becoming UK director, global project management in 1996. Dr Blackwell joined Scotia Pharmaceuticals plc in 1998, where he served as executive director, drug development.
